Stigma and discrimination: Barrier for ending AIDS by 2030 and achieving the 90-90-90 targets by 2020
DOI:
https://doi.org/10.53638/phpma.2019.v7.i1.p01Abstract
In order to be able to mirror the achievements of other countries towards 90-90-90, addressing stigma and discrimination towards key populations and people with HIV+ is crucial. Without these efforts ending the AIDS epidemic by 2030 will be challenging to realize and remain a lofty aspiration.
References
UNAIDS. The AIDS epidemic can be ended by 2030. Geneva, Switzerland. 2016.
UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Joint United Nations Programme on AIDS. Geneva, Switzerland. 2014.
Andrade HB, Shinotsuka CR, da Silva IRF, Donini CS, Yeh Li H, de Carvalho FB, et al. Highly active antiretroviral therapy for critically ill HIV patients: a systematic review and meta-analysis. PLoS ONE. 2017; 12(10): e0186968. https://doi.org/10.1371/journal.pone.0186968
Montaner JSG, Lima VD, Harrigan PR, Lourenc L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS ONE. 2014; 9(2): e87872.
UNAIDS. Data 2018, Joint United Nations Programme on AIDS. Geneva, Switzerland. 2018.
Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in KwaZulu-Natal, South Africa. Science. 2013; 339:966-971.
Rodger A, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIVpositive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019; 393(10189): 2428-38.
Cohen MS, Ying QC, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. New England Journal of Medicine. 2016; 375(9): 830–839. DOI:10.1056/NEJMoa1600693.
UNAIDS. Data 2017, Joint United Nations Programme on AIDS. Geneva, Switzerland. 2017.
Brown Alison E, Hayes Rosalie, Noori Teymur, Azad Yusef, Amato-Gauci Andrew J., Pharris Anastasia, et al. The ECDC Dublin declaration monitoring network. HIV in Europe and Central Asia: progress in 2018 towards meeting the UNAIDS 90-90-90 targets. Euro Surveill. 2018; 23(48):pii=1800622. DOI:10.2807/1560-7917. ES.2018.23.48.1800622
Ministry of Health of Indonesia, Directorate General Diseases Prevention and Control. Estimasi jumlah populasi kunci HIV di Indonesia tahun 2016 [Estimation of HIV key population in Indonesia 2016]. Jakarta, 2017.
Ministry of Health of Indonesia, Directorate General Diseases Prevention and Control. Kajian epidemiologi HIV di Indonesia tahun 2016 [Report on epidemiology of HIV in Indonesia 2016]. Jakarta, 2017.
Shannon K, Strathdee SA, Goldenberg SM, Duff P, Mwangi P, Rusakova, M, et al., Global epidemiology of HIV among female sex workers: influence of structural determinants. Lancet. 2015; 385(9962): 55–71. DOI:10.1016/S0140-6736(14)60931-4.
Baral S, Beyrer C, Muessig K, Poteat T, Wirtz AL, Decker MR, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12: 538–49. DOI:10.1016/S1473-3099(12)70066-X
Lazuardi E, Newman CE, Tasya IA, Rowe E, Wirawan DN, Wisaksana R, et al. Understanding the social influences on engaging key populations with HIV prevention: a qualitative study with men who have sex with men in three Indonesian cities. AIDS Education and Prevention. 2019; 31(3): 206–223.
United Nations Country Team Indonesia. Report for the universal periodic review of Indonesia, 27th Session, April-May 2017. Available at: https://uprdoc.ohchr.org/uprweb/downloadfile.aspx?filename=3939&file
Januraga P, Reekie J, Mulyani T, Lestari BW, Iskandar S, Wisaksana R, et al. The cascade of HIV care among key populations in Indonesia. Lancet HIV. 2018; Published Online August 21, 2018 http://dx.doi.org/10.1016/S2352-3018(18)30148-6
Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, Bangsberg DR, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. Journal of the International AIDS Society. 2013; 16(Suppl 2):18640. DOI: 10.7448/IAS.16.3.18640
Corless IB, Hoyt AJ, aawwTyer-Viola L, Sefcik E, Kemppainen J, Holzemer WL, et al. 90-90-90-Plus: Maintaining adherence to antiretroviral therapies. AIDS Patient Care and STDs. 2017; 31(5): 227-236. DOI: 10.1089/apc.2017.0009
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Dewa Nyoman Wirawan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
**Creative Commons Attribution 4.0 International License (CC BY 4.0)**
*Welcome to the world of open collaboration and shared creativity! The Creative Commons Attribution 4.0 International License (CC BY 4.0) empowers creators to share their work with the world while maintaining certain rights.*
**Key Points:**
1. **Freedom to Share:** CC BY 4.0 allows creators to share their work globally, granting others the freedom to use, remix, and build upon it.
2. **Attribution Requirement:** Users can use the work for any purpose, even commercially, as long as they provide appropriate credit to the original creator.
3. **Flexibility:** Applicable to various content types—text, images, music, videos—the license fosters a diverse range of creations.
**Common Use Cases:**
- **Education:** Widely used for educational materials, promoting open learning environments.
- **Research:** Applied to scholarly articles, accelerating the dissemination of knowledge.
**How to Use:**
1. **Share:** Share your work with the world, marking it with the CC BY 4.0 license.
2. **Attribution:** Users, when utilizing the work, must provide proper attribution to honor the original creator.
**Conclusion:**
CC BY 4.0 contributes to a more open and collaborative digital landscape. Join the movement of shared knowledge and creativity!
*For full license details, visit [Creative Commons](https://creativecommons.org/licenses/by/4.0/).*
